EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effect of Patient Body Mass, Age, and Renal Function on the Assessment of Cerebrovascular Reactivity During the Acetazolamide Challenge

Rahim Ismail, Denes Szekeres, Derek George, Derrek Schartz, Mark Manganaro, Zoe Williams, Matthew Bender, Henry Wang

Clinical Neuroimaging · 2025

DOI: 10.1002/neo2.70017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Neuroimaging, 2025. Verfasst von Rahim Ismail und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cerebrovascular reactivity (CVR) is a blood flow index which reflects locoregional vascular health in the brain. CVR is measured using MRI with an acetazolamide (AZM) challenge. While 1000 mg of AZM is often used, there is no clear consensus on dosing. We postulate the physiologic variables—age, creatinine, and weight—may impact variation in CVR dynamics, leading to poor study reliability in different patient groups. The present study reviewed patients who underwent AZM challenge MRI examinations at our institution from 2014 to 2022.

Methods

Changes in CVR were evaluated at 5 and 10 min post‐AZM challenge as function of weight, BMI, age, and creatinine. Univariable data was analyzed using Pearson correlation coefficient.

Results

Forty‐nine patients were included in this retrospective review. Forty‐seven percent of patients identified as female, with a mean age of 55 ± 13 years, a mean BMI of 29 ± 6 kg/m 2 , and mean creatinine clearance of 0.96 ± 0.32 mg/dL. BMI was found to be significantly negatively associated with AZM response at 5 min ( r = −0.63, p = 0.002) and 10 min ( r = −0.44, p = 0.045) post‐AZM challenge. However, the present study did not demonstrate changes to CVR by creatinine or age.

Conclusions

CVR is underestimated with increasing body mass, possibly explained by undersaturation of carbonic anhydrase with current standardized dosages. Ubiquitous weight‐based dosing would be a superior and more reproducible predictor for CVR than standardized regimens, particularly at BMI extremes where CVR variability is significant.

Zitieren

APA

Ismail, R., Szekeres, D., George, D., Schartz, D., Manganaro, M., Williams, Z., Bender, M., & Wang, H. (2025). Effect of Patient Body Mass, Age, and Renal Function on the Assessment of Cerebrovascular Reactivity During the Acetazolamide Challenge. Clinical Neuroimaging. https://doi.org/10.1002/neo2.70017

Vancouver

Ismail R, Szekeres D, George D, Schartz D, Manganaro M, Williams Z, et al. Effect of Patient Body Mass, Age, and Renal Function on the Assessment of Cerebrovascular Reactivity During the Acetazolamide Challenge. Clinical Neuroimaging. 2025. doi:10.1002/neo2.70017

BibTeX
@article{Ismail2025,
  author = {Ismail, Rahim and Szekeres, Denes and George, Derek and Schartz, Derrek and Manganaro, Mark and Williams, Zoe and Bender, Matthew and Wang, Henry},
  title = {Effect of Patient Body Mass, Age, and Renal Function on the Assessment of Cerebrovascular Reactivity During the Acetazolamide Challenge},
  journal = {Clinical Neuroimaging},
  year = {2025},
  doi = {10.1002/neo2.70017}
}
Kostenlos starten →